Citation: Xie Hong-Lei, Liu Chun-Chi, Li Yi-Qun, Bai Chang-Lin, Hao Chen-Zhou, Guo Jing, Luo Chang-Qun, Zhao Dong-Mei, Cheng Mao-Sheng. Synthesis of novel β-propanamides to inhibit cholesteryl ester transfer protein (CETP)[J]. Chinese Chemical Letters, ;2017, 28(2): 260-263. doi: 10.1016/j.cclet.2016.10.016 shu

Synthesis of novel β-propanamides to inhibit cholesteryl ester transfer protein (CETP)

Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China

Corresponding author: Zhao Dong-Mei, medchemzhao@163.com
Received Date: 6 June 2016
Revised Date: 9 August 2016
Accepted Date: 9 August 2016
Available Online: 21 February 2016

Figures(2)

A novel series of β-propanamide derivatives as inhibitors of cholesteryl ester transfer protein (CETP) were synthesized. Previously, H3 (IC₅₀ 2 μmol/L) was observed to inhibit CETP moderately (Xie et al., 2016). Structural modifications based on H3 led to discovery of the successful CETP inhibitor, known as 1-methyl-4-arylpyrazole. Using a similar approach, compound Q08 was identified as a highly potent CETP inhibitor with an IC₅₀ of 490 nmol/L in vitro.
- CETP inhibitor,
- Cardiovascular disease,
- High-density lipoprotein,
- Low-density lipoprotein,
- In vitro
1. [1]
  P.G. McGovern, J.S. Pankow, E. Shahar. Recent trends in acute coronary heart disease-mortality morbidity, medical care, and risk factors[J]. N. Engl. J. Med., 1996,334:884-890. doi: 10.1056/NEJM199604043341403
2. [2]
  P.J. Barter, H.B. Brewer, M.J. Chapman. Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis[J]. Arterioscler. Thromb. Vasc. Biol., 2003,23:160-167. doi: 10.1161/01.ATV.0000054658.91146.64
3. [3]
  M.J. Chapman, G. Assmann, J.C. Fruchart. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk:the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C[J]. Curr. Med. Res. Opin., 2004,20:1253-1268. doi: 10.1185/030079904125004402
4. [4]
  R.B. Ruggeri. Cholesteryl ester transfer protein:pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis[J]. Curr. Top. Med. Chem., 2005,5:257-264. doi: 10.2174/1568026053544506
5. [5]
  A.R. Tall. CETP inhibitors to increase HDL cholesterol levels[J]. N. Engl. J. Med., 2007,356:1364-1366. doi: 10.1056/NEJMe078029
6. [6]
  R.W. Clark, T.A. Sutfin, R.B. Ruggeri. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein:an initial multidose study of torcetrapib[J]. Arterioscler. Thromb. Vasc. Biol., 2004,24:490-497. doi: 10.1161/01.ATV.0000118278.21719.17
7. [7]
  G. Assmann, H. Schulte, A.V. Eckardstein. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport[J]. Atherosclerosis, 1996,124:S11-S20. doi: 10.1016/0021-9150(96)05852-2
8. [8]
  P. Barter, A.M. Gotto, J.C. Larosa. HDL cholesterol very low levels of LDL cholesterol, and cardiovascular events[J]. N. Engl. J. Med., 2007,357:1301-1310. doi: 10.1056/NEJMoa064278
9. [9]
  P.M. Kearney, A. Keech, J. Simes. Statins and diabetes-authors' reply[J]. Lancet, 2008,371:117-125. doi: 10.1016/S0140-6736(08)60104-X
10. [10]
  C. Baigent, A. Keech, P.M. Kearney. Efficacy and safety of cholesterollowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins[J]. Lancet, 2005,366:1267-1278. doi: 10.1016/S0140-6736(05)67394-1
11. [11]
  X.Y. Qiu, A. Mistry, M.J. Ammirati. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules[J]. Nat. Struct. Mol. Biol., 2007,14:106-113. doi: 10.1038/nsmb1197
12. [12]
  S.P. Liu, A. Mistry, J.M. Reynolds. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors[J]. J. Biol. Chem., 2012,287:37321-37329. doi: 10.1074/jbc.M112.380063
13. [13]
  D. Dalvie, W.C. Chen, C.H. Zheng. Pharmacokinetics metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans[J]. Drug Metab. Dispos., 2008,36:2185-2198. doi: 10.1124/dmd.108.023176
14. [14]
  J.M. Mckenney, M.H. Davidson, C.L. Shear. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin[J]. J. Am. Coll. Cardiol., 2006,48:1782-1790. doi: 10.1016/j.jacc.2006.06.066
15. [15]
  M. Vergeer, E.S.G. Stroes. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors[J]. Am. J. Cardiol., 2009,104:32E-38E. doi: 10.1016/j.amjcard.2009.09.017
16. [16]
  D. Bloomfield, G.L. Carlson, A. Sapre. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients[J]. Am. Heart J., 2009,157:352-360. doi: 10.1016/j.ahj.2008.09.022
17. [17]
  G.G. Schwartz, A.G. Olsson, M. Abt. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N. Engl. J. Med., 2012,367:2089-2099. doi: 10.1056/NEJMoa1206797
18. [18]
  H.L. Xie, Y.Q. Li, C.L. Bai. Discovery of novel N, N'-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo[J]. Bioorg. Med. Chem., 2016,24:1811-1818. doi: 10.1016/j.bmc.2016.03.002
1. [1]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
2. [2]
  Jiajia Lv , Jie Gao , Hongyu Li , Zeli Yuan , Nan Dong . Rational design of hydroxytricyanopyrrole-based probes with high affinity and rapid visualization for amyloid-β aggregates in vitro and in vivo. Chinese Chemical Letters, 2024, 35(5): 108940-. doi: 10.1016/j.cclet.2023.108940
3. [3]
  Zian Lin , Yingxue Jin . Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) for Disease Marker Screening and Identification: A Comprehensive Experiment Teaching Reform in Instrumental Analysis. University Chemistry, 2024, 39(11): 327-334. doi: 10.12461/PKU.DXHX202403066
4. [4]
  Huyi Yu , Renshu Huang , Qian Liu , Xingfa Chen , Tianqi Yu , Haiquan Wang , Xincheng Liang , Shibin Yin . Te-doped Fe3O4 flower enabling low overpotential cycling of Li-CO2 batteries at high current density. Chinese Journal of Structural Chemistry, 2024, 43(3): 100253-100253. doi: 10.1016/j.cjsc.2024.100253
5. [5]
  Qingyun Hu , Wei Wang , Junyuan Lu , He Zhu , Qi Liu , Yang Ren , Hong Wang , Jian Hui . High-throughput screening of high energy density LiMn_1-xFe_xPO₄ via active learning. Chinese Chemical Letters, 2025, 36(2): 110344-. doi: 10.1016/j.cclet.2024.110344
6. [6]
  Yunfei Shen , Long Chen . Gradient imprinted Zn metal anodes assist dendrites-free at high current density/capacity. Chinese Journal of Structural Chemistry, 2024, 43(10): 100321-100321. doi: 10.1016/j.cjsc.2024.100321
7. [7]
  Renshu Huang , Jinli Chen , Xingfa Chen , Tianqi Yu , Huyi Yu , Kaien Li , Bin Li , Shibin Yin . Synergized oxygen vacancies with Mn2O3@CeO2 heterojunction as high current density catalysts for Li–O2 batteries. Chinese Journal of Structural Chemistry, 2023, 42(11): 100171-100171. doi: 10.1016/j.cjsc.2023.100171
8. [8]
  Longsheng Zhan , Yuchao Wang , Mengjie Liu , Xin Zhao , Danni Deng , Xinran Zheng , Jiabi Jiang , Xiang Xiong , Yongpeng Lei . BiVO₄ as a precatalyst for CO₂ electroreduction to formate at large current density. Chinese Chemical Letters, 2025, 36(3): 109695-. doi: 10.1016/j.cclet.2024.109695
9. [9]
  Xu Huang , Kai-Yin Wu , Chao Su , Lei Yang , Bei-Bei Xiao . Metal-organic framework Cu-BTC for overall water splitting: A density functional theory study. Chinese Chemical Letters, 2025, 36(4): 109720-. doi: 10.1016/j.cclet.2024.109720
10. [10]
  Maitri Bhattacharjee , Rekha Boruah Smriti , R. N. Dutta Purkayastha , Waldemar Maniukiewicz , Shubhamoy Chowdhury , Debasish Maiti , Tamanna Akhtar . Synthesis, structural characterization, bio-activity, and density functional theory calculation on Cu(Ⅱ) complexes with hydrazone-based Schiff base ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(7): 1409-1422. doi: 10.11862/CJIC.20240007
11. [11]
  Xiaoxiao Wang , Bolun Wang , Fenfen Ji , Jie Yan , Jiacheng Fang , Doudou Zhang , Ji Xu , Jing Ji , Xinran Hao , Hemi Luan , Yanjun Hong , Shulan Qiu , Min Li , Zhu Yang , Wenlan Liu , Xiaodong Cai , Zongwei Cai . Discovery of plasma biomarkers for Parkinson’s disease diagnoses based on metabolomics and lipidomics. Chinese Chemical Letters, 2024, 35(11): 109653-. doi: 10.1016/j.cclet.2024.109653
12. [12]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
13. [13]
  Tao Liu , Xuwei Han , Xueyi Sun , Weijie Zhang , Ke Gao , Runan Min , Yuting Tian , Caixia Yin . An activated fluorescent probe to monitor NO fluctuation in Parkinson’s disease. Chinese Chemical Letters, 2025, 36(3): 110170-. doi: 10.1016/j.cclet.2024.110170
14. [14]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
15. [15]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
16. [16]
  Chao Chen , Wenwen Yu , Guangen Huang , Xuelian Ren , Xiangli Chen , Yixin Li , Shenggui Liang , Mengmeng Xu , Mingyue Zheng , Yaxi Yang , He Huang , Wei Tang , Bing Zhou . Asymmetric macrocyclization enabled by Rh(Ⅲ)-catalyzed CH activation: Enantioenriched macrocyclic inhibitor of Zika virus infection. Chinese Chemical Letters, 2024, 35(11): 109574-. doi: 10.1016/j.cclet.2024.109574
17. [17]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
18. [18]
  Zhexin Chen , Yuqing Shi , Fang Zhong , Kai Zhang , Furong Zhang , Shenghong Xie , Zhongbin Cheng , Qian Zhou , Yi-You Huang , Hai-Bin Luo . Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects. Chinese Chemical Letters, 2025, 36(4): 109956-. doi: 10.1016/j.cclet.2024.109956
19. [19]
  Aolei Tan , Xiaoxiao Ma . Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics. Chinese Chemical Letters, 2024, 35(8): 109276-. doi: 10.1016/j.cclet.2023.109276
20. [20]
  Jingting Wang , Yuanyuan Chen , Linlin Han , Shasha Xia , Xingyao Zhang , Peng Xue , Yuejun Kang , Jian Ming , Zhigang Xu . Microenvironment responsive pod-structured astaxanthin nanocarrier for ameliorating inflammatory bowel disease. Chinese Chemical Letters, 2024, 35(7): 109029-. doi: 10.1016/j.cclet.2023.109029

Get Citation

PDF

XML

Metrics

PDF Downloads(1)
Abstract views(677)
HTML views(30)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142